BF.B
57
4
LB
70
2
A
47
8
WFC
58
4
DE
78
2
ALL
58
5
STX
66
2
TXT
76
3
NEM
69
-3
KLAC
72
2
WEC
53
3
STI
4
3
HRL
30
4
SIG
69
5
FITB
73
3
IRM
62
2
AMT
47
2
MRK
55
2
O
75
7
XEL
74
3
BF.B
57
4
LB
70
2
A
47
8
WFC
58
4
DE
78
2
ALL
58
5
STX
66
2
TXT
76
3
NEM
69
-3
KLAC
72
2
WEC
53
3
STI
4
3
HRL
30
4
SIG
69
5
FITB
73
3
IRM
62
2
AMT
47
2
MRK
55
2
O
75
7
XEL
74
3
Financhill
Back

Cosmo Pharmaceuticals NV 10K Form

Buy
81

CMOPF
Cosmo Pharmaceuticals NV

Last Price:
$158.04
Seasonality Move:
11.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CMOPF News And Ratings

See the #1 stock for the next 7 days that we like better than CMOPF

CMOPF Financial Statistics

Sales & Book Value

Annual Sales: $288.6M
Cash Flow: $0
Price / Cash Flow: 35.29
Annual Sales: $33.30
Price / Book: 2.32

Profitability

EPS (TTM): 3.57210
Net Income (TTM): $59.6M
Gross Margin: $237.5M
Return on Equity: 15.06%
Return on Assets: 10.72%

Cosmo Pharmaceuticals NV Earnings Forecast

Key Cosmo Pharmaceuticals NV Financial Ratios

  • The Gross Profit Margin over the past 21 years for CMOPF is 82.29%.
  • The Selling, General & Administrative Expenses for CMOPF have been equal to 13.60% of Gross Profit Margin.
  • The Research & Development expenses have been 14.26% of Revenue.
  • The Interest Expense is 0.09% of Operating Income.
  • The Net Earning history of CMOPF is 49.92% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 12 years.

Cosmo Pharmaceuticals NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: CMOPF
Website: cosmopharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.85
Quick Ratio: 4.48

Price-to-Earnings

Trailing P/E Ratio: 18
Forward P/E Ratio: 0

CMOPF Technical Analysis vs Fundamental Analysis

Buy
81
Cosmo Pharmaceuticals NV (CMOPF) is a Buy

Is Cosmo Pharmaceuticals NV a Buy or a Sell?